乳腺癌的全身治疗：放射科医生入门指南。

Systemic treatment in breast cancer: a primer for radiologists.

作者信息

Michaels Aya Y, Keraliya Abhishek R, Tirumani Sree Harsha, Shinagare Atul B, Ramaiya Nikhil H

机构信息

Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

出版信息

Insights Imaging. 2016 Feb;7(1):131-44. doi: 10.1007/s13244-015-0447-4. Epub 2015 Nov 13.

UNLABELLED

Cytotoxic chemotherapy, hormonal therapy and molecular targeted therapy are the three major classes of drugs used to treat breast cancer. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), (18)F-FDG positron emission tomography (PET)/CT and bone scintigraphy each have a distinct role in monitoring response and detecting drug toxicities associated with these treatments. The purpose of this article is to elucidate the various systemic therapies used in breast cancer, with an emphasis on the role of imaging in assessing treatment response and detecting treatment-related toxicities.

TEACHING POINTS

• Cytotoxic chemotherapy is often used in combination with HER2-targeted and endocrine therapies. • Endocrine and HER2-targeted therapies are recommended in hormone-receptor- and HER2-positive cases. • CT is the workhorse for assessment of treatment response in breast cancer metastases. • Alternate treatment response criteria can help in interpreting pseudoprogression in metastasis. • Unique toxicities are associated with cytotoxic chemotherapy and with endocrine and HER2-targeted therapies.

未标注

细胞毒性化疗、激素治疗和分子靶向治疗是用于治疗乳腺癌的三大类药物。诸如计算机断层扫描（CT）、磁共振成像（MRI）、（18）F-FDG正电子发射断层扫描（PET）/CT和骨闪烁显像等成像方式在监测治疗反应以及检测与这些治疗相关的药物毒性方面各自具有独特作用。本文的目的是阐明用于乳腺癌的各种全身治疗方法，重点是成像在评估治疗反应和检测治疗相关毒性中的作用。